---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-002982"
form_type: "8-K"
ticker: "ABT"
cik: "0000001800"
company_name: "ABBOTT LABORATORIES"
filed_at: "2026-01-22T23:59:59+00:00"
generated_at: "2026-05-16T08:51:49.260090+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Abbott Q4 adj EPS $1.50 (+12% YoY); FY2025 revenue $44.3B; FY2026 adj EPS guide $5.55–$5.80

## Summary
- Q4 GAAP EPS $1.01, adjusted EPS $1.50 (+12% YoY); revenue $11.46B (+4.4% reported, +3.8% ex-COVID).
- FY2025 adjusted EPS $5.15 (+10% YoY); revenue $44.3B (+5.7% reported, +6.7% ex-COVID).
- FY2026 guidance: organic sales growth 6.5%-7.5%; adjusted EPS $5.55-$5.80 (midpoint +10%).
- Medical Devices sales +12.3% reported (+10.4% organic); CGM sales $2.0B up 15% reported.
- Agreed to acquire Exact Sciences (cancer diagnostics); close expected Q2 2026. FDA OK for Volt PFA System.

## SEC filing metadata
- accession: 0001628280-26-002982
- form_type: 8-K
- ticker: ABT
- cik: 0000001800
- company_name: ABBOTT LABORATORIES
- filed_at: 2026-01-22T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1800/000162828026002982/0001628280-26-002982-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1800/000162828026002982/abt-20260122.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-002982
- JSON: https://secwatch.observer/filing/0001628280-26-002982.json
- Plain text: https://secwatch.observer/filing/0001628280-26-002982.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.